Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a note issued to investors on Monday. The firm currently has a $83.00 target price on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 47.63% from the stock’s previous close.

Several other research analysts also recently issued reports on SRPT. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Piper Jaffray Cos. reissued a “sell” rating and issued a $6.00 price objective on shares of Sarepta Therapeutics in a research note on Saturday, June 4th. Robert W. Baird reissued an “outperform” rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Vetr cut shares of Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 price objective on the stock. in a research note on Wednesday, June 8th. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $51.01.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.88% on Monday, reaching $56.22. The company’s stock had a trading volume of 8,767,424 shares. The company’s market cap is $2.69 billion. The company has a 50 day moving average price of $29.05 and a 200 day moving average price of $21.62. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $58.87.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/royal-bank-of-canada-upgrades-sarepta-therapeutics-inc-srpt-to-outperform-2.html

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the business posted ($0.87) EPS. On average, analysts anticipate that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, VP Jayant Aphale sold 35,000 shares of the stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the sale, the vice president now owns 21,490 shares in the company, valued at approximately $1,074,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the period. State Street Corp raised its stake in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the period. BlackRock Fund Advisors raised its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in Sarepta Therapeutics during the first quarter valued at approximately $13,506,000. Hedge funds and other institutional investors own 72.09% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.